Author: Hardik Vatsa

Hydrogels are materials that mimic the softness and flexibility of biological tissues, making them invaluable in medicine for tasks like wound healing and drug delivery. Semiconductors, on the other hand, power the electronics that define our modern world, offering functionalities like sensing, amplification, and light-based modulation. Bringing these two materials together could transform the way we design devices for biomedical use, but this combination has been difficult to achieve—until now.

Researchers have developed a process called solvent affinity–induced assembly that embeds a hydrophobic semiconducting polymer into a hydrogel without compromising its softness or stretchiness. This innovation allows the creation of a hybrid material that behaves like biological tissue while also carrying out advanced electronic functions. The process starts by mixing a semiconducting polymer called p(g2T-T) with a hydrogel-forming monomer, acrylic acid, in a solvent known as dimethyl sulfoxide (DMSO). Ultraviolet (UV) light is used to cross-link the mixture into a stable double-network structure, and the DMSO is then replaced with water. This crucial solvent exchange step transforms the material into a soft, water-filled hydrogel while preserving the semiconductor’s electronic properties.

The resulting material exhibits a modulus, or stiffness, as low as 81 kilopascals, similar to biological tissues, and can stretch up to 150% without breaking. Despite its softness, it maintains high charge-carrier mobility, a measure of how efficiently it conducts electricity, comparable to that of rigid semiconductors. The hydrogel’s porous structure further enhances its performance by promoting molecular interactions with surrounding fluids, which improves its ability to sense and respond to biochemical signals.

This breakthrough has significant implications for medicine and technology. Because the hybrid material matches the mechanical properties of living tissues, it reduces the likelihood of immune responses when used in the body. Its combination of biocompatibility and electronic functionality enables a range of possibilities, such as real-time biosensing to detect subtle changes in the body, like shifts in pH or glucose levels. It also has potential for light-based therapies, delivering precise stimulation to tissues or nerves through photomodulation. Furthermore, its softness and stretchability make it ideal for wearable or implantable devices that conform to the surface of organs or skin without causing discomfort or damage.

By merging the tissue-like properties of hydrogels with the advanced electronic capabilities of semiconductors, this innovation represents a major step forward in bioelectronics. The ability to create soft, biocompatible materials with integrated electronic functionality opens up new possibilities for smarter, more adaptable medical devices. From diagnostic tools to therapeutic implants, this hydrogel-semiconductor hybrid is poised to reshape the landscape of biomedicine.

As research continues, this hybrid material could become a cornerstone of next-generation bioelectronics, paving the way for seamless integration between biology and technology.

Reference:
Dai, Y., Wai, S., Li, P., Shan, N., Cao, Z., Li, Y., Wang, Y., Liu, Y., Liu, W., Tang, K., Liu, Y., Hua, M., Li, S., Li, N., Chatterji, S., Fry, H. C., Lee, S., Zhang, C., Weires, M., Sutyak, S., … Wang, S. (2024). Soft hydrogel semiconductors with augmented biointeractive functions. Science (New York, N.Y.), 386(6720), 431–439. https://doi.org/10.1126/science.adp9314

In the intricate world of eye surgery, where precision is crucial, researchers are turning to innovative solutions to improve patient safety and outcomes. A recent breakthrough at Johns Hopkins University introduces a “glowing” gel that enhances surgical visibility and reduces the risk of complications. This novel tool, developed at the Wilmer Eye Institute and the Department of Biomedical Engineering, combines fluorescein and hyaluronic acid (a naturally occurring substance in the eye) to create a gel that “lights up” under a specific blue light.

The glow arises from a reaction between fluorescein, a fluorescent dye widely used in medical diagnostics, and hyaluronic acid. When fluorescein absorbs light from a blue light source, it emits a greenish-yellow glow, a property known as fluorescence. Hyaluronic acid acts as the gel’s base, providing a biocompatible medium that integrates seamlessly into surgical applications. The team at Johns Hopkins optimized the concentration of fluorescein so that the gel would glow brightly without altering its physical properties or interfering with the surgeon’s view of delicate eye structures.

Eye surgeries, such as cataract removal, often rely on ophthalmic viscosurgical devices (OVDs)—gel-like substances that stabilize the eye during procedures. While OVDs are indispensable, their use comes with challenges. Any gel left behind post-surgery can increase eye pressure, cause irritation, or lead to complications requiring additional intervention. Current techniques to locate and remove residual OVDs depend on the surgeon’s experience and careful observation under white light, which may not always reveal minute amounts of leftover material.

This new fluorescein-infused gel, dubbed “conjOVD”, addresses this issue by making the gel instantly visible under cobalt blue light (CBL). Surgeons can now detect and remove every trace of the gel before concluding the operation. This innovation could significantly improve surgical outcomes, as even a slight reduction in post-operative complications benefits patients immensely.

During laboratory tests, the gel demonstrated a unique advantage: it remains clear under normal white light but becomes vividly fluorescent under blue light. This dual property ensures the gel doesn’t obstruct the surgeon’s view during delicate steps of the surgery while enabling precise removal at the end.

While still in the testing phase, this glowing gel has the potential to become a game-changing addition to surgical toolkits. It reflects a growing trend in combining chemistry, engineering, and medicine to address challenges in modern surgery.

By improving visibility during operations and reducing risks associated with retained OVD, this tool promises to make eye surgeries quicker, safer, and more effective for patients. As further studies confirm its efficacy, this technology could soon be a standard feature in operating rooms worldwide, bringing in a new era of precision eye care.

Reference:

Rocher, Erick E. BS; Eghrari, Allen O. MD, MPH. Fluorescein-conjugated hyaluronic acid enables visualization of retained ophthalmic viscosurgical device in anterior chamber. Journal of Cataract & Refractive Surgery 50(10):p 1058-1064, October 2024. | DOI: 10.1097/j.jcrs.0000000000001503